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Abstract
Introduction: In this study, we aimed to investigate ultrasonographic (US) changes suggestive of gouty arthritis in
the hyaline cartilage, joints and tendons from asymptomatic individuals with hyperuricemia.
Methods: We conducted a cross-sectional, controlled study including US examinations of the knees and first
metatarsal-phalangeal joints (first MTPJs), as well as of the tendons and enthesis of the lower limbs. Differences
were estimated by c
2 or unpaired t-tests as appropriate. Associations were calculated using the Spearman’s
correlation coefficient rank test.
Results: Fifty asymptomatic individuals with hyperuricemia and 52 normouricemic subjects were included.
Hyperechoic enhancement of the superficial margin of the hyaline cartilage (double contour sign) was found in
25% of the first MTPJs from hyperuricemic individuals, in contrast to none in the control group (P < 0.0001). Similar
results were found on the femoral cartilage (17% versus 0; P < 0.0001). Patellar enthesopathy (12% versus 2.9%; P =
0.01) and tophi (6% versus 0; P = 0.01) as well as Achilles enthesopathy (15% versus 1.9%; P = 0.0007) were more
frequent in hyperuricemic than in normouricemic individuals. Intra-articular tophi were found in eight
hyperuricemic individuals but in none of the normouricemic subjects (P = 0.003).
Conclusions: These data demonstrate that morphostructural changes suggestive of gouty arthritis induced by
chronic hyperuricemia frequently occur in both intra- and extra-articular structures of clinically asymptomatic
individuals.
Introduction
Serum urate (SU) concentration represents the balance
between the breakdown of purines and the rate of uric
acid renal excretion. Its solubility threshold is approxi-
mately 7 mg/dL, and when exceeded, interstitial fluids
become oversaturated, which in turn increases the likeli-
hood of monosodium urate (MSU) crystal tissue deposi-
tion [1]. The MSU crystal deposition can be clinically
expressed as gouty arthritis, tophi formation, urate
nephropathy or urolithiasis [2].
While the usefulness of urate-lowering treatment in
patients with clinical manifestations of hyperuricemia
such as gouty arthritis or nephropathy has been largely
established, its use in asymptomatic hyperuricemic indi-
viduals is still the object of several controversies [3].
This could in part be related to the limited evidence
about the subclinical musculoskeletal involvement in
asymptomatic individuals with hyperuricemia [4].
Although the best imaging method to investigate the
presence of MSU crystal deposits in the early stages has
not yet been established [5], ultrasound (US) has been
demonstrated to be a valid imaging modality to detect
musculoskeletal involvement in patients with gout [6-9].
The main US findings related to MSU crystal deposition
include hyperechoic enhancement of the superficial
margin of the hyaline cartilage (double contour sign),
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any medium, provided the original work is properly cited.hyperechoic spots within tendons and soft tissues, tophi
and bone erosions [7,10,11]. Additionally, an increase of
blood flow surrounding the MSU deposits detected by
power Doppler (PD) has been described as an indicator
of inflammatory activity [5,7].
In erosive arthritides, musculoskeletal US has been
shown to be a valuable imaging method to confirm
early structural damage [12]. Moreover, both magnetic
resonance imaging and US are useful advanced imaging
techniques to demonstrate occult destructive arthropa-
thy in patients with gout and normal plain radiographs
[13]. However, to date, there is only a single US study
demonstrating the existence of tophaceous deposits in
asymptomatic hyperuricemic subjects; remarkably, that
study was focused on the assessment of tendons and
synovium pathology of knees and ankles [5]. On the
basis of the understanding that MSU tissue deposits
occur at multiple sites (especially on the hyaline carti-
lage), the present study was aimed at investigating the
existence of subclinical musculoskeletal involvement in
the hyaline cartilage, tendons, soft tissues and lower-
limb joints (knees, ankles and first metatarsal-phalangeal
joints (first MTPJs)) from asymptomatic individuals with
hyperuricemia by means of US.
Materials and methods
Patients
The study was performed on 50 consecutive patients
with SU concentrations ≥7.0 mg/dL on at least two
occasions within the past 2 years who had attended the
outpatient clinics of the rheumatology, cardiology and
nephrology departments and in 52 healthy controls with
SU <7 mg/dL recruited from among the hospitals’ staff
and patients’ relatives.
The study was conducted according to the Declaration
of Helsinki. Ethical approval for the study was obtained
from both the Instituto Nacional de Cardiología and
Instituto Nacional de Rehabilitación (Mexico City,
Mexico) and informed consent was obtained from all
participants.
Clinical and laboratory assessments
All individuals underwent a detailed evaluation, includ-
ing clinical history, musculoskeletal examination and
laboratory testing. All study participants were asked to
recall whether any musculoskeletal symptom had ever
occurred. Both hyperuricemic subjects and controls
underwent a clinical examination by an expert clinical
rheumatologist, who recorded swelling and tenderness
elicited by pressure, mobilization and contraction
against resistance of the corresponding areas of study,
to confirm the absence of musculoskeletal involve-
ment. Hyperuricemic subjects without any clinical evi-
dence of arthritis or enthesopathy underwent an US
examination. Exclusion criteria were age <18 years,
current or previous use of urate-lowering agents and
nonsteroidal anti-inflammatory drugs or corticoster-
oids, malignancy or other concomitant rheumatic
inflammatory conditions.
Fasting blood samples were collected from all indivi-
duals no longer than 3 days prior to US evaluation. SU
concentrations were measured in duplicate by spectro-
photometry (Hitachi 902; Roche Diagnostics, Indianapo-
lis, IN, USA), mean values were used for analyses, and
the results were expressed in milligrams per deciliter.
US assessment
US examinations were performed using MyLab25 (Esaote
Biomedica, Genoa, Italy) equipped with a 6- to 18-MHz
broadband linear transducer. All patients were scanned by
two rheumatologists (CP and CH-D) trained in musculos-
keletal US. Representative images were acquired and digi-
tally recorded, and an electronic file was created for each
patient and used to complete a standardized pro forma off-
line file. Consensus between sonographers was obtained
before the beginning of the study on both the scanning
technique to adopt and the sonographic findings reported
in the standardized pro forma file by scanning different
individuals not involved in the present study. Discrepan-
cies between sonographers were found in fewer than 10%
of the images and were resolved by consensus.
The following anatomical areas were bilaterally
scanned: knee (suprapatellar pouch, quadriceps tendon
insertion, proximal and distal patellar tendon insertions
and femoral hyaline cartilage), ankle (tibiotalar joint,
posterior tibialis, peroneus longus and brevis tendons, as
well as Achilles tendon) and first MTPJs (synovial mem-
brane and hyaline cartilage).
All of the US examinations were performed using a
multiplanar technique in accordance with the European
League Against Rheumatism guidelines for musculoske-
letal ultrasound in rheumatology [14]. Dynamic exami-
nation with flexion-extension was carried out to
investigate the superficial margin of the hyaline cartilage
in the first MTPJs.
US examination of the first MTPJs and tibiotalar joints,
p e r o n e u sl o n g u sa n db r e v i sa sw e l la sp o s t e r i o rt i b i a l i s
tendons were performed with the patient in a supine
position with the knee in flexion (30°). The supine posi-
tion with extended lower limbs was adopted for the
quadriceps and patellar tendons and the suprapatellar
pouch, while the Achilles tendons were examined while
the patient was lying prone with the feet hanging over
the edge of the examination table in flexion (90°).
Each anatomical area was scanned in gray scale mode
to detect morphostructural changes and subsequently
with the PD technique to detect abnormal blood flow.
Blood flow was examined with a pulse repetition
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6 and 8 MHz. Attention was given not to compress the
tissues under examination to avoid a “blanching” of the
PD signal due to the transducer pressure.
US interpretation
US definitions described by the Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) Spe-
cial Interest Group were adopted for the study [15].
Joint effusion was recorded when anechoic or hypoe-
choic joint cavity widening was detected, while synovial
hypertrophy was recognized as the presence of abnormal
hypo- or hyperechoic tissue within the joint cavity.
Additionally, hyperechoic enhancement of the superficial
margin of hyaline cartilage was regarded as a surrogate
of MSU crystal deposition (double contour sign),
whereas inhomogeneous tendon and/or entheseal thick-
ening and intratendinous hyperechoic bands defined the
presence of enthesopathy or tendinopathy. Erosion was
defined as a definite cortical interruption with a step-
down contour defect in both longitudinal and transverse
views. Enthesophyte was defined as a step-up promi-
nence at the end of a normal bone profile.
Statistical analysis
Frequencies (expressed as percentages) were used to
describe categorical data and compared using the c
2
test. Means (± SD) were used for continuous variables,
and differences were assessed by unpaired t-tests. Corre-
lations were evaluated by using the Spearman’s coeffi-
cient (rs), while odds ratios (OR) were used to weigh the
associations between hyperuricemia and US findings.
P < 0.05 was considered significant. All analyses were
two-tailed and were performed using GraphPad Prism
4.02 software (GraphPad Software, San Diego, CA, USA).
Results
In all, 50 individuals with hyperuricemia and 52 controls
with normouricemia were studied. Table 1 shows the
demographic and clinical characteristics of the
participants. Of note, both the mean age and the fre-
quency of diseases associated with the metabolic syn-
drome were higher in hyperuricemic patients than in
normouricemic individuals.
A total of 100 knees, ankles and first MTPJs in
patients with hyperuricemia and 104 in the normourice-
mic controls were studied. Seven (7%) of 100 knees
from hyperuricemic patients showed joint cavity widen-
ing, whereas only two knees (1.9%; P =N S )f r o m
healthy controls revealed this abnormality. The propor-
tion of joint cavity widening in the first MTPJs was 52%
in hyperuricemic patients compared with 24% in the
normouricemic group (P < 0.0001) (Table 2).
On femoral hyaline cartilage, the double contour sign
(Figure 1A) was present in 17 of 100 knees from hyper-
uricemic patients in contrast to none in the control
group (P < 0.0001), giving an odds ratio (OR) of 43.8
(95% confidence interval (95% CI), 2.9 to 739). The pre-
valence of the double contour sign in the first MTPJs
(Figure 1B) was also higher in hyperuricemic patients
(25% vs. 0%; P < 0.0001), with an OR of 34.3 (95% CI,
4.5 to 259). However, no correlation between SU con-
centration and the presence of the double contour sign
was found (rs -0.06; 95% CI, -0.3 to 0.2).
Tophi formation was found in 18 individuals with
hyperuricemia but in none of the normouricemic con-
trols (P < 0.0001), producing an OR of 46.8 (95% CI, 2.7
to 789); however, mean SU concentrations were similar
r e g a r d l e s st h ep r e s e n c eo ft o p h i( 8 . 1 3±0 . 8 9v s .8 . 1 3±
0.99 mg/dL; P = NS). Intra-articular tophi were found in
eight (8%) hyperuricemic patients but in none of the
normouricemic controls (P = 0.003).
Tendon examinations showed patellar enthesopathy
(12% vs. 2.9%; P = 0.01) and intratendinous tophi (6%
vs. 0; P =0 . 0 1 ) ,a sw e l la sA c h i l l e se n t h e s o p a t h y
Table 1 Clinical and demographic data of the study
populations
Parameter Hyperuricemic
(n = 50)
Normouricemic
(n = 52)
P value
Mean age ± SD, yr 55.7 ± 16.6 47.3 ± 10.9 0.003
Male gender, n (%) 33 (66%) 35 (67%) NS
Serum urate, mg/dL
(mean ± SD)
8.1 ± 0.9 5.47 ± 0.90 <0.0001
Associated diseases
Hypertension, n 24 (48%) 0 <0.0001
Diabetes mellitus, n 13 (26%) 0 <0.0001
Hyperlipidemia, n 8 (16%) 0 0.002
SD, standard deviation; NS, not significant.
Table 2 Pathological ultrasonographic findings in joints
a
Anatomical site and
US findings
Hyperuricemic
(n = 100
joints)
Normouricemic
(n = 104
joints)
P
value
First MTP joint, n (%)
Double contour sign 25 (25%) 0 <0.0001
Joint cavity widening
(synovial fluid/
hypertrophy)
52 (52%) 25 (24%) <0.0001
Power Doppler signal 0 0 NS
Bone erosion 12 (12%) 6 (5.7%) NS
Knee, n (%)
Double contour sign
(femoral hyaline
cartilage)
17 (17%) 0 <0.0001
Joint cavity widening
(synovial fluid/
hypertrophy)
7 (7%) 2 (1.9%) NS
aUS, ultrasonographic; MTP, metatarsal-phalangeal joint; NS, not significant.
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hyperuricemic patients than in normouricemic indivi-
duals (Table 3). Tenosynovitis was found only in three
hyperuricemic patients (two in the peroneus longus ten-
d o na n do n ei nt h ep o s t e r i o rt i b i a l i st e n d o n ) .N oP D
signal was found in any anatomical area examined.
Discussion
The present study was aimed at demonstrating a wide
spectrum of subclinical structural damage in asympto-
matic individuals with hyperuricemia. Our results sup-
port the hypothesis that the morphostructural changes
suggestive of gouty arthritis induced by hyperuricemia
Figure 1 The double contour sign. Hyperechoic enhancement of the chondrosynovial interface secondary to the monosodium urate crystal
deposition. (A) Transversal scan of the femoral cartilage surface. (B) Longitudinal view of the plantar aspect in the first metatarsal-phalangeal
joint.
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asymptomatic individuals.
Chronically elevated SU has not usually been considered
to play a pathogenic role in tissue damage. However, large
prospective population studies are challenging this notion,
since they have found that SU levels are reliable and con-
sistent predictors of progression for endothelial dysfunc-
tion [16], coronary artery disease [17,18] and renal failure
[2]. In this line of thought, our results support the exis-
tence of both intra- and extra-articular tissue damage
caused by the persistent elevation of SU [5]. The presence
of MSU crystals in the synovial fluid from asymptomatic
individuals with hyperuricemia has been demonstrated on
the basis of polarized light microscopy since the early
1980s [4]. In accord with this evidence, the double contour
sign has been described solely in gout and seems to repre-
sent the preference of SU to crystallize on the surface of
cartilage [7,11,19]. Even when the underlying mechanisms
for this preference need further clarification, it has been
shown that the normal components of cartilage chondroi-
tin sulfate and phosphatidylcholine facilitate the nuclea-
tion and subsequent crystallization of MSU [20]. As
confirmation of the presence of MSU in the hyaline carti-
lage, Thiele and Schlesinger [21] recently demonstrated
the disappearance of the double contour sign in patients
with gout successfully treated with urate-lowering agents
who had maintained SU levels below 6 mg/dL for at least
7 months. Also, tophi formation detected in our study
further confirmed the presence of MSU crystal tissue
deposition in both intra- and extra-articular structures
from asymptomatic hyperuricemic individuals as pre-
viously suggested [5]. This may strengthen the need for
treatment necessity in asymptomatic individuals with
hyperuricemia and indisputable US features of MSU crys-
tal tissue deposition such as the double contour sign or
the presence of tophi [3].
Recently, US has been shown to be of value in revealing
subclinical joint and tendon inflammation in patients
with other inflammatory conditions such as arthritis
[22,23], psoriasis [24] and Sjögren’s syndrome [25]. This
prompted us to investigate its ability to identify the invol-
vement of the hyaline cartilage, tendons and joints in
individuals with asymptomatic hyperuricemia and no
signs of inflammation or musculoskeletal complaints.
Our results are in agreement with a previous report [5].
Indeed, Puig et al. [5] studied 35 asymptomatic indivi-
duals with hyperuricemia and found tophi formation in
both tendons and synovium in 34% of patients, with a
special preference for the distal patellar tendon. Here we
have extended the US evaluation to other anatomical
sites characteristically involved in gout, such as the hya-
line cartilage and first MTPJs, and have shown that MSU
crystal deposition and structural damage in these loca-
tions may be even greater and more frequent than in ten-
dons. Additionally, the present study was carried out in a
higher number of participants and included a normouri-
cemic, healthy control group. Further differences
between studies are related to our findings of bone ero-
sion and synovial fluid and/or hypertrophy, both of
which are common features of gout but were not
assessed in the study by Puig et al. [5].
We are aware that our study has limitations, including
the lack of validation for morphostructural changes by
other techniques, the absence of longitudinal follow-up to
determine the predictive value of US in the development
of established gout, the lack of MSU crystal diagnosis in
those patients with US changes suggestive of gouty arthri-
tis, and the low sensitivity of the PD used. Furthermore,
the sonographers were not blinded to whether they were
examining a hyperuricemic individual or a control. Finally,
the demographic differences between study groups,
namely, younger healthy participants, cannot be ignored.
Table 3 Pathological ultrasonographic findings in tendons
a
Anatomical site US finding Hyperuricemic
(n = 100 tendons)
Normouricemic
(n = 104 tendons)
P value
Quadriceps tendon, n (%) Enthesopathy 5 (5%) 5 (4.8%) NS
Tophus 2 (2%) 0 NS
Patellar tendon Enthesopathy 12 (12%) 3 (2.9%) 0.01
(proximal/distal), n (%) Tophus 6 (6%) 0 0.01
Posterior tibialis tendon Enthesopathy 0 0 NS
Tenosynovitis 1 (1%) 0 NS
Tophus 0 0 NS
Peroneus tendon Enthesopathy 0 0 NS
(brevis/longus), n (%) Tenosynovitis 2 (2%) 0 NS
Tophus 0 0 NS
Achilles tendon, n (%) Enthesopathy 15 (15%) 2 (1.9%) 0.0007
Tophus 2 (2%) 0 NS
aUS, ultrasonographic; NS, not significant.
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should be the object of longitudinal investigations.
Ongoing follow-up of the patients recruited in the pre-
sent study will provide further information regarding
the predictive value of US findings for the development
of gouty arthritis.
Conclusions
Our US findings open a new battlefront in the current
debate about the use of urate-lowering agents in asymp-
tomatic patients with persistent hyperuricemia. Also,
these findings support musculoskeletal US as a useful,
noninvasive tool to detect anatomical damage in the
hyaline cartilage, synovial tissue and tendons of asymp-
tomatic individuals with hyperuricemia.
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